biostudies-literatureUnknown8(6)Mazzucconi MG<h4>Abstract</h4>A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial responseBlood advances1529-1540https://www.ebi.ac.uk/biostudies/studies/S-EPMC10966179biostudies-literaturePrednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.PMC10966179Paoloni FRanalli PRossi EDi Ianni MGiuffrida ACCrugnola MAvvisati GDe Stefano VSibilla SMartino BRivolti EPalandri FPatriarca ACarella AMRuggeri MCarli GBattistini RSiragusa SSargentini VLugli EGentile MGugliotta LFortuna SPolverelli NMusto PTafuri ASantoro CVianelli NBocchia MRago ARodeghiero FD'Adda MMazzucconi MGBaldacci EFerretti AZaja FFazi PDi Renzo NVincelli IDKrampera MfalsePrednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.<h4>Abstract</h4>A debate exists regarding which type of corticosteroids (standard-dose prednisone [PDN] or high-dose dexamethasone [HD-DXM]) is the best first-line treatment for adult patients with newly diagnosed untreated primary immune thrombocytopenia (pITP). An ad hoc study compared PDN with HD-DXM in newly diagnosed untreated patients with pITP (aged ≥18 but ≤80 years, platelet count of ≤20 or >20 but <50 × 109/L, and bleeding score of ≥8). Patients were randomised to receive PDN 1 mg/kg per day from days 0 to 28 (Arm A) or HD-DXM 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B). Fifty-nine of 113 patients (52.2%) were randomized to Arm A and 54 of 113 (47.8%) to Arm B. In evaluable patients, total initial responses (complete response [CR], partial response2024-01-01T00:00:00Z2024 Mar2025-04-21T21:28:14.113Z2025-04-05T18:25:46.363ZS-EPMC109661793823101710.1182/bloodadvances.2023010975